- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03730636
Procalcitonin and Duration of AntiBiotherapy In Late Onset Sepsis of Neonate (PROABIS)
The duration of antibiotic (ATB) therapy in late onset sepsis (LOS) of the neonate is currently not based on scientific data. The current PROABIS trial will study the use of a biological marker, procalcitonin (PCT), to guide ATB therapy duration in neonates with LOS.
Our hypothesis is that the use of procalcitonin guidance can reduce of 30% the duration of ATB treatment without increasing recurrence of infection and mortality.
Study Overview
Detailed Description
Randomized controlled multicenter open trial comparing the efficacy of PCT guided strategy (superiority aspect) and safety (non-inferiority aspect) versus usual strategy in LOS of the neonate.
After inclusion, patients are randomly assigned (in a 1:1 ratio) to duration of ATB therapy according to PCT guidance (experimental group) or to standard of care (control group).
Experimental group:
For patients randomly assigned in the PCT-guided group, a PCT concentration is measured at D0 (randomisation), at D2 and then, every two days until PCT value is equal or below 0.5 ng/mL.
The physician in charge of the neonate will be strongly encouraged to stop ATB treatment as soon as the PCT value is equal or below 0.5 ng/mL.
Control group:
In the control group, management of LOS and treatment are based on the attending clinician's practice and according to the usual practice (No PCT dosage).
In both groups data will be collected at the follow-up visit (day 14±2 after randomization) or the day of discharge from the hospital (if before 14±2 days) and at the end of the study visit (day 28± 2 after randomization) In case of transfer to another service or hospital or known re hospitalization before day28, outcomes will be collected from the service receiving the patient.
A phone call will be made to the parents, only in case of discharge before 28 days. following randomization. This phone call will be made 28± 2 days after randomization to identify adverse outcomes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Delphine MITANCHEZ, PU-PH
- Phone Number: 00 331 44 73 61 91
- Email: delphine.mitanchez@aphp.fr
Study Locations
-
-
Tours
-
Paris, Tours, France, 37044
- Department of Neonatology Bretonneau Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Neonates born at 24 or more weeks of gestation,
- Aged over 96 hours of life, i.e. from the 5th day of life and less than 45 gestational weeks at diagnosis of assumed or proven LOS,
- Weight at the inclusion ≥ 700 g,
- Treated by ATB therapy for less than 48 hours,
- When the physician decides to continue de empiric ATB treatment beyond the initial 48-h period,
- Written informed consent signed by both parents (in the absence of one of the two parents the day of inclusion, the new born can be included with the signature of only one parent.The second parent must give oral consent and sign the consent form as soon as possible "before day 28"),
- Affiliation to a social security system (recipient or assign).
Exclusion Criteria:
- Neonates with non-indication of ATB treatment following the 48h-initial empiric period.
- ATB treatment within the 48h before the current episode of infection; except for taking antibiotics for prophylactic purposes (ex: digestive decontamination), pulmonary-targeted treatments for atypical germs and antibiotics by local means (ex.: eye drops).
- Patients diagnosed with severe infections (meningitis and/or septic shock) or needing prolonged therapy (ex: endocarditis, bone infection, deep seated infection, abscesses). Septic shock is defined by fluid resistant hypotension requiring vasopressor therapy.
- Infections not contracted during the hospitalization in the neonatal period or revealed more than 48 hours after hospital discharge.
- Neonates during treatment by extracorporeal membrane oxygenation or extra-corporeal circulation, and within the 72h after the end of the treatment.
- Neonates previously included in the Proabis study.
- Participation with another interventional study involving human subjects or being in the exclusion period at the end of a previous study involving human subjects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PCT-guided strategy
Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
|
Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
|
No Intervention: Usual practice (control group)
Management of LOS and treatment is based on the attending clinician's practice and according to the usual practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of the PCT guided ATB strategy on the duration of ATB treatment compared to usual ATB strategy
Time Frame: up to 28 days
|
Number of days between start and end of treatment, including treatment of the recurrence, if any
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-inferiority of the PCT-guided ATB strategy to usual strategy on mortality at 28 days following randomization
Time Frame: 28 days
|
Mortality rate at 28 days following randomization
|
28 days
|
Non-inferiority of the PCT-guided ATB strategy to usual strategy on recurrence of infection within 72 hours after ending ATB therapy.
Time Frame: 28 days
|
Proportion of infants with a treatment failure and recurrence of infection within 72h after ending ATB treatment and requiring additional course of ATBs.
|
28 days
|
Description on the total number of assumed or proven bacterial infections within the 28 days following randomization.
Time Frame: 28 days
|
Total number of assumed or proven bacterial infections within the 28 days following randomization, excluding the primary infection and its recurrence
|
28 days
|
To compare the cumulative dose of received ATB treatment (mg/kg).
Time Frame: Day 28
|
Cumulative dose of ATB treatment (mg/kg), defined as the total dose (in mg/kg) between start and end of treatment, including treatment of the recurrence, if any
|
Day 28
|
To describe the bacteriological epidemiology of LOS
Time Frame: 28 days
|
Recording of all the bacteriological species identified in blood or other samples during the LOS
|
28 days
|
Proportion of patients with bronchopulmonary dysplasia
Time Frame: 28 days
|
Proportion of patients with bronchopulmonary dysplasia in order to assess the proportion of patients with bronchopulmonary dysplasia at 28 days
|
28 days
|
Proportion of patients with at least one event between randomization and day 28 among death, recurrence of infection and bronchopulmonary dysplasia.
Time Frame: 28 days
|
Proportion of patients with at least one event between randomization and day 28 among death, recurrence of infection and bronchopulmonary dysplasia in order to evaluate the endpoint combining death or recurrence of infection or bronchopulmonary dysplasia
|
28 days
|
Antibiotics free days at D28
Time Frame: 28 days
|
Antibiotics free days at D28is defined as the number of days alive without any antibiotics at day 28.
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Delphine MITANCHEZ, PU-PH, Department of Neonatology Bretonneau Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 170928J
- 2018-AO1396-49 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on PCT dosage
-
Centre Hospitalier Universitaire, AmiensUnknownNon Small Cells Lung CancerFrance
-
St. Justine's HospitalCompletedBacteremia | Bacterial Infection | Procalcitonin | Fever Without SourceCanada
-
University Hospital, CaenUnknown
-
Tel-Aviv Sourasky Medical CenterUnknownPneumothorax | Hypoxia | Bleeding | Atelectasis | PneumomediastinumIsrael
-
Tel-Aviv Sourasky Medical CenterUnknownPneumothorax | Hypoxia | Bleeding | Atelectasis | PneumomediastinumIsrael
-
David Lynch FoundationNot yet recruitingSuicidal Ideation | Depressive Symptoms | Alcohol Use, Unspecified | Ptsd
-
The Learning CorpCompletedAphasia, AcquiredUnited States
-
The University of AkronBrown University; Summa Health System; Pacific Institute for Research and Evaluation and other collaboratorsCompleted
-
University of Missouri-ColumbiaCompletedVentilator Associated PneumoniaUnited States
-
US Department of Veterans AffairsCompleted